Mesenchymal stem cell intravenous injection for osteoporosis diseases

By isolating and cultured MSC and endothelial progenitor cells from umbilical cord tissue, a high content of MSC preparation was prepared, which solved the problem of adverse reactions and uncertainties in the MSC preparations in the prior art, achieved the stability and safety of the preparation, and was suitable for the treatment of osteoporosis diseases.

CN119950553APending Publication Date: 2025-05-09HELP STEM CELL INNOVATIONS CO LTD
2 Cites 0 Cited by

Patent Information

Application Number
CN202510265855.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2022-09-09
Publication Date
2025-05-09

AI Technical Summary

Technical Problem

Existing MSC preparations often experience adverse reactions after treatment, such as fever, and the characteristics of human MSCs are not certain due to the differences in multiple parameters.

Method used

By co-isolating and cultured MSCs and endothelial progenitor cells obtained from umbilical cord tissue, controlling the content of endothelial progenitor cells, avoiding the introduction of animal-derived ingredients, and preparing preparations containing ≥90% MSC cells to ensure the stability and safety of the preparations.

Benefits of technology

The optimal performance maintenance of MSC cells was achieved, the preparation had good stable performance and had no toxic side effects, was suitable for large-scale production, and its safety and therapeutic effect were verified in animal models.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the field of cell preparations, and relates to a mesenchymal stem cell intravenous injection for osteoporosis diseases, the injection comprises an injection, MSC and endothelial progenitor cells, the MSC and the endothelial progenitor cells are obtained by co-separation culture from umbilical cord tissues; wherein the content of MSC cells is not less than 90%, and the content of endothelial progenitor cells is not more than 10%; the injection comprises normal saline, a compound electrolyte injection, a dextran 40 glucose injection or a hyaluronic acid injection. The preparation containing the MSC cells is simple and clear in component, free of toxic and side effects and good in stability.
Need to check novelty before this filing date? Find Prior Art